Advertisement

Advertisement

2025 ASCO GI

Colorectal Cancer

Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E...

Colorectal Cancer

Experimental Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E...

Colorectal Cancer

Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup

An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastroin...

colorectal cancer

Anna Martling, MD, PhD, on the ALASCCA Trial in Colorectal Cancer

The randomized, double-blind, multicenter, placebo-controlled ALASCCA Trial screened 3,508 patients across 33 hospitals in Sweden, Denmark, Finland, and Norway for eligibility. They either had stage I...

colorectal cancer

Cathy Eng, MD, on the FRESCO-2 Study in Metastatic Colorectal Cancer

Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, reported on findings from the FRESCO-2 study, focusing on overall survival with fruquintinib vs placebo after adjusting for subsequent anticancer the...

Colorectal Cancer
Genomics/Genetics
Issues in Oncology

Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer

First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) chemotherapy regimen may be effective in patients with B...

colorectal cancer

Scott Kopetz, MD, PhD, FACP, on the BREAKWATER Study in BRAF V600–Mutant Metastatic Colorectal Cancer

The open-label, global, randomized phase III BREAKWATER study was an  analysis of first-line encorafenib plus cetuximab plus chemotherapy in patients with BRAF V600E–mutant metastatic colorectal cance...

Colorectal Cancer

New Findings on Aspirin and Risk of Colorectal Cancer Recurrence

According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily after treatment ends may reduce the risk of cancer recurr...

Colorectal Cancer

New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer

Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors, may reduce the risk of developing colon cancer. A recent CALGB/SWOG study reveale...

neuroendocrine tumors

Susumu Hijioka, MD, on the Phase III STARTER-NET Study in GEP-NET

Susumu Hijioka, MD, of the National Cancer Center, Tokyo, discusses results from the phase III JCOG1901 STARTER-NET study in patients with gastroenteropancreatic neuroendocrine (GEP-NET) tumors. The s...

colorectal cancer

Thierry André, MD, on First Results From CheckMate 8HW

Thierry André, MD, of Hôpital Saint-Antoine, presented first results from the ongoing phase III CheckMate 8HW trial comparing nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite inst...

colorectal cancer

Aasma Shaukat, MD, MPH, on A Blood-Based Test for Colorectal Cancer Screening

Aasma Shaukat, MD, MPH, of NYU Langone, presented results from the PREEMPT CRC study, which evaluated the clinical performance of an investigational blood-based screening test for detecting molecular ...

Gastrointestinal Cancer
Neuroendocrine Tumors

Everolimus/Lanreotide vs Everolimus in Gastroenteropancreatic Neuroendocrine Tumors

A recent study found that a combination of the mTOR inhibitor everolimus and the hormone-blocking drug lanreotide extended progression-free survival compared with everolimus alone for people with some...

Colorectal Cancer

Does a New Blood-Based Screening Test Accurately Detect Colorectal Cancer Risk?

Colorectal cancer is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease. Although screening ...

Colorectal Cancer

ChatGPT Has Limitations in Clinical Utility for Colorectal Cancer but May Be Useful for Patient Education

A study evaluating ChatGPT’s ability to accurately respond to patient inquiries regarding colon cancer by comparing its responses with assessments from expert clinical oncologists found that questions...

Advertisement

Advertisement




Advertisement